Pharmacological restoration of selective autophagy for the treatment of skeletal...
Pharmacological restoration of selective autophagy for the treatment of skeletal disorders
Lysosomal storage disorders (LSDs) are a family of inherited genetic diseases characterized by lysosomal dysfunction, with a consequent block in the degradative capacity of the cell. The skeleton is one of the most affected organs...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
.BLASTED2
Identification of molecular targets for the treatment of the...
100K€
Cerrado
LYSOBONE
Cellular and molecular analysis of the skeletal pathologies...
159K€
Cerrado
RTI2018-098672-B-I00
TERAPIA GENICA NO VIRAL PARA EL TRATAMIENTO DE ENFERMEDADES...
145K€
Cerrado
SAF2011-25431
ANALISIS GENETICOS EN TRASTORNOS QUE AFECTAN A CELULAS OSEAS...
182K€
Cerrado
LysoMod
Genetic and Small Molecule Modifiers of Lysosomal Function
1M€
Cerrado
RTC-2016-5686-1
Desarrollo de tratamientos para enfermedades raras de depósi...
323K€
Cerrado
Información proyecto RE-STORE
Duración del proyecto: 18 meses
Fecha Inicio: 2020-12-12
Fecha Fin: 2022-06-30
Líder del proyecto
FONDAZIONE TELETHON ETS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
150K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Lysosomal storage disorders (LSDs) are a family of inherited genetic diseases characterized by lysosomal dysfunction, with a consequent block in the degradative capacity of the cell. The skeleton is one of the most affected organs in LSD patients and current therapies are largely ineffective for the treatment of bone and cartilage manifestations. Thanks to the support of the ERC-starting grant BONEPHAGY we demonstrated that the degradation of the endoplasmic reticulum fragments via lysosome/autophagy pathway (ER-phagy) exerts ER quality control functions that are essential for secretion of procollagens. This process is impaired in LSD chondrocytes and osteoblasts, the cartilage and bone forming cells, respectively and accounts, at least in part, for the skeletal growth retardation observed in LSD mouse models. Prompted by these exciting findings, RE-STORE proposes to develop a novel cell-based integrated screening platform to identify selective ER-phagy inducers to target the skeletal phenotype of LSDs and contribute significantly to their development into innovative therapeutics. The access to proprietary library, through a collaboration with an industrial partner, and the set-up of a rapid hit confirmation in disease animal models will allow RE-STORE to establish a complete drug development pipeline for the selected hits. RE-STORE is an ambitious project that aims to develop an innovative substrate-to-lysosome screening approach for the study of selective autophagy and to identify new therapies for the so-called ER-storage disorders characterized by accumulation of misfolded polypeptides in the lumen of the ER.